Potential biomarkers for immunotherapy in non-small-cell lung cancer
Author:
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s10555-022-10074-y.pdf
Reference153 articles.
1. Osmani, L., Askin, F., Gabrielson, E., et al. (2018). Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy[J]. Seminars in Cancer Biology, 52(Pt 1), 103–109.
2. Arbour, K. C., & Riely, G. J. (2019). Systemic therapy for locally advanced and metastatic non-small cell lung cancer: A review[J]. JAMA, 322(8), 764–774.
3. Camidge, D. R., Doebele, R. C., & Kerr, K. M. (2019). Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC[J]. Nature Reviews. Clinical Oncology, 16(6), 341–355.
4. Reck, M., Rodríguez-Abreu, D., Robinson, A. G., et al. (2016). Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer[J]. New England Journal of Medicine, 375(19), 1823–1833.
5. Gandhi, L., Rodriguez-Abreu, D., Gadgeel, S., et al. (2018). Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. New England Journal of Medicine, 378(22), 2078–2092.
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Preparation of Biomimetic Selenium–Baicalein Nanoparticles and Their Targeted Therapeutic Application in Nonsmall Cell Lung Cancer;Molecular Pharmaceutics;2024-08-06
2. Heterogeneity of lymphocyte subsets in predicting immune checkpoint inhibitor treatment response in advanced lung cancer: an analysis across different pathological types, therapeutic drugs, and age groups;Translational Lung Cancer Research;2024-06
3. The Triterpenoid CDDO-Methyl Ester Reduces Tumor Burden, Reprograms the Immune Microenvironment, and Protects from Chemotherapy-Induced Toxicity in a Preclinical Mouse Model of Established Lung Cancer;Antioxidants;2024-05-21
4. First-line immunotherapy for advanced non-small cell lung cancer: current progress and future prospects;Cancer Biology & Medicine;2023-12-26
5. Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies;Molecular Cancer;2023-07-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3